This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotechrss

Amicus Acquires Scioderm, Adds Drug for Rare Skin Disorder to Pipeline

  • Tickers in this article:
  • FOLD

Acquiring Scioderm gives Amicus another late-stage orphan disease drug expected to have pivotal trial data in the first half of next year.

08/31/15 - 06:01 AM EDT

U.S. Stocks Open Lower as Personal Income and Spending Climb

U.S. stocks opened lower Friday as personal income and spending both rose in July.

08/28/15 - 09:48 AM EDT

Predicting the Outcome of the Biomarin and Sarepta FDA Drug Reviews

Predicting the Outcome of the Biomarin and Sarepta FDA Drug Reviews

Approving both the Biomarin and Sarepta drugs for Duchenne muscular dystrophy is the most politically expedient decision the FDA can make.

08/27/15 - 12:45 PM EDT

U.S. Stocks Open Lower as Personal Income and Spending Climb

U.S. Stocks Open Lower as Personal Income and Spending Climb

U.S. stocks opened lower Friday as personal income and spending both rose in July.

08/28/15 - 09:48 AM EDT

Biotech Selloff Has No Effect on Cellectis Advances: CEO

Biotech Selloff Has No Effect on Cellectis Advances: CEO

The selloff in immunotherapy stocks is purely market-based and does not reflect the stunning advances in the cancer fighting space, said Dr. Andre Choulika, CEO of Cellectis S.A.

08/26/15 - 11:29 AM EDT

Biotech Selloff Does Not Dim Immunotherapy Advances Says Cellectis CEO

Biotech Selloff Does Not Dim Immunotherapy Advances Says Cellectis CEO

The selloff in immunotherapy stocks is purely market-based and does not reflect the stunning advances in the cancer fighting space, said Dr. Andre Choulika, CEO of Cellectis S.A.

08/26/15 - 11:05 AM EDT

Specialty Pharma Firms That Could Be Potential Targets for Generics Giants

Specialty Pharma Firms That Could Be Potential Targets for Generics Giants

Companies are running out of acquisition targets and as a result, specialty pharma firms are now in the M&A spotlight as acquisitive drugmakers search for new ways to fuel growth.

08/25/15 - 02:48 PM EDT

An Inside Look at Biotech Investor Pros Dealing With Market Meltdown

An Inside Look at Biotech Investor Pros Dealing With Market Meltdown

Last night, I exchanged emails with a number of investors who run dedicated health care funds. I wanted to know how they navigated Monday's market selloff.

08/25/15 - 07:38 AM EDT

Northwest Bio Forced to Temporarily Halt Enrollment of Brain Tumor Vaccine Study (Update)

Northwest Bio Forced to Temporarily Halt Enrollment of Brain Tumor Vaccine Study (Update)

Enrollment of new patients into the DCVax-L study is suspended until the company "submits certain information from the trial for regulatory review," Northwest Bio said.

08/24/15 - 08:53 AM EDT

Pfizer (PFE) Stock Lower, Receives Regulatory Approval for Hospira Purchase

Pfizer (PFE) Stock Lower, Receives Regulatory Approval for Hospira Purchase

  • Tickers in this article:
  • PFE

Pfizer (PFE) shares are down despite the company receiving regulatory approval for its $15.23 billion purchase of smaller rival Hospira (HSP).

08/24/15 - 11:28 AM EDT

Bear Chart of the Day: iShares Nasdaq Biotechnology ETF Isn't Healthy

Bear Chart of the Day: iShares Nasdaq Biotechnology ETF Isn't Healthy

  • Tickers in this article:
  • IBB

The exchange-traded fund will reach oversold levels if it falls to the $330-$335 area from the current $346.

08/21/15 - 02:15 PM EDT

How Google Wants to Help Change Diabetes Forever

How Google Wants to Help Change Diabetes Forever

Google Life Sciences and DexCom are joining forces to change the way the country's 29 million diabetics measure blood sugar, hoping to eliminate the finger prick forever.

08/21/15 - 02:38 PM EDT

AbbVie or Baxalta: Which Is the Better Biopharma Investment Today?

AbbVie or Baxalta: Which Is the Better Biopharma Investment Today?

AbbVie and Baxalta have many similarities. Here are the key differences that make one a better investment than the other.

08/21/15 - 10:15 AM EDT

Quant Picks: Three Managed Health Care Companies to Buy Now

Quant Picks: Three Managed Health Care Companies to Buy Now

Here are some of the best managed health care stocks our algorithm says you should consider looking at.

08/21/15 - 08:30 AM EDT

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Markets

Chart of I:DJI
DOW 16,528.03 -114.98 -0.69%
S&P 500 1,972.18 -16.69 -0.84%
NASDAQ 4,776.5080 -51.8170 -1.07%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs